-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Critical Analysis: Fresh Tracks Therapeutics (FRTX) and The Competition
Critical Analysis: Fresh Tracks Therapeutics (FRTX) and The Competition
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 277 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it compare to its rivals? We will compare Fresh Tracks Therapeutics to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.
Profitability
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
Get Fresh Tracks Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.23% | -37.17% |
Risk and Volatility
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Fresh Tracks Therapeutics and its rivals, as reported by MarketBeat.com.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 895 | 3857 | 10720 | 160 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 61.29%. As a group, "Biological products, except diagnostic" companies have a potential upside of 70.07%. Given Fresh Tracks Therapeutics' rivals higher probable upside, analysts plainly believe Fresh Tracks Therapeutics has less favorable growth aspects than its rivals.
Earnings & Valuation
This table compares Fresh Tracks Therapeutics and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.30 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -2.01 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
7.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 46.5% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are owned by company insiders. Comparatively, 16.3% of shares of all "Biological products, except diagnostic" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 8 of the 10 factors compared.
About Fresh Tracks Therapeutics
(Get Rating)
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 277 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it compare to its rivals? We will compare Fresh Tracks Therapeutics to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.
新鮮軌道治療（NASDAQ：FRTX — 獲取評級）是「生物製品，除了診斷」行業的 277 家上市公司之一，但它與競爭對手相比如何？我們將根據其風險、分析師建議、機構所有權、股息、收益、盈利能力和估值的強度，將 Fresh Track 治療與同類公司進行比較。
Profitability
盈利
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
此表格比較了 Fresh Track 治療學及其競爭對手的淨利潤，股權回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.23% | -37.17% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 新鮮軌道治療 | -453.11% | -133.55% | -108.52% |
| 新鮮的軌道治療競爭對手 | -4,576.34% | -104.23% | -37.17% |
Risk and Volatility
風險及波動性
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
新鮮軌道治療的測試版為 0.29，這表明其股價比標普 500 少了 71％ 的波動性。相比之下，新鮮軌道治療的競爭對手的測試版為 0.75，這表明他們的平均股價比標普 500 少 25％ 的波動性。
Analyst Recommendations
分析師推薦
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 895 | 3857 | 10720 | 160 | 2.65 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 新鮮軌道治療 | 0 | 0 | 0 | 0 | N/A |
| 新鮮的軌道治療競爭對手 | 895 | 3857 | 10720 | 160 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 61.29%. As a group, "Biological products, except diagnostic" companies have a potential upside of 70.07%. Given Fresh Tracks Therapeutics' rivals higher probable upside, analysts plainly believe Fresh Tracks Therapeutics has less favorable growth aspects than its rivals.
新鮮軌道治療目前的共識價格目標為 4.00 美元，表明潛在的上行空間為 61.29％。作為一個集團，「生物製品，除了診斷」的公司具有 70.07％ 的潛在上漲空間。鑑於 Fresh Track 治療 '競爭對手可能較高的上行空間, 分析師清楚地認為，Fresh Track 治療具有比競爭對手不那麼有利的增長方面.
Earnings & Valuation
盈利及估值
This table compares Fresh Tracks Therapeutics and its rivals top-line revenue, earnings per share and valuation.
該表比較了 Fresh Track 治療學及其競爭對手的頂級收入，每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.30 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -2.01 |
| 總收入 | 淨收入 | 市盈比率 | |
| 新鮮軌道治療 | 400 萬美元 | -3,947 百萬美元 | -0.30 |
| 新鮮的軌道治療競爭對手 | 七億七千七百萬美元 | 一億四千六百八十四萬元 | -2.01 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
新鮮軌道治療 '競爭對手具有更高的收入和收益比新鮮軌道治療.Fresh Track 治療以比競爭對手更高的價格盈利比進行交易，這表明它目前比其行業中的其他公司更昂貴。
Insider and Institutional Ownership
內幕和機構所有權
7.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 46.5% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are owned by company insiders. Comparatively, 16.3% of shares of all "Biological products, except diagnostic" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
7.7％ 的新軌道治療股票由機構投資者擁有。相比之下，所有「生物產品（診斷除外）」公司的 46.5％ 股份由機構投資者擁有。4.5％ 的 Fresh Track 治療股份由公司內部人員擁有。相比之下，所有「生物製品（診斷除外）」公司的股份的 16.3％ 由公司內部人士擁有。強大的機構所有權表明，大型資金經理，對沖基金和捐贈基金認為一家公司有望實現長期增長。
Summary
摘要
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 8 of the 10 factors compared.
新鮮軌道治療對手在 8 個因素中擊敗了新鮮軌道治療的 10 個因素。
About Fresh Tracks Therapeutics
關於新鮮軌道治療
(Get Rating)
(取得評分)
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
Fresh Track 治療, Inc. 從事用於治療皮膚疾病的處方治療藥物的開發。其管道由針對以下適應症治療的新分子實體組成：多汗症，過敏性接觸性皮炎，雄激素性脫髮，皮膚 T 細胞淋巴瘤和牛皮癬。該公司由雷金納德 ·L· 哈迪和安德魯 ·D· 斯克勞爾於 2009 年成立，總部位於科羅拉多州博爾德。
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收新鮮軌道治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Fresh Track 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧